Stock analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) in a report issued on Thursday. The firm set a “sell” rating on the stock.
Ayala Pharmaceuticals Price Performance
ADXS stock opened at $0.56 on Thursday. The company has a market cap of $5.97 million, a P/E ratio of -0.07 and a beta of 1.63. The stock’s fifty day moving average price is $0.67 and its 200-day moving average price is $0.73. Ayala Pharmaceuticals has a 1 year low of $0.50 and a 1 year high of $1.95.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last posted its quarterly earnings results on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Featured Articles
- Five stocks we like better than Ayala Pharmaceuticals
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Business Services Stocks Investing
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Health Care Stocks Explained: Why You Might Want to Invest
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
